Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Atmos Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.01 (market cap $39.89B), while Atmos Energy Corporation trades at $178.54 (market cap $29.41B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Atmos Energy Corporation pays a 2.27% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ATO | |
|---|---|---|
Market Cap | $39.89B | $29.41B |
Sector | Health | Utilities |
52-Week High | $491.22 | $192.25 |
52-Week Low | $278.09 | $154.10 |
Enterprise Value | $38.15B | $38.91B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Atmos Energy (ATO) trades at $176.2, up 0.85% today, with a neutral technical signal. The stock shows strong fundamentals with revenue growth to $4.70B in 2025 and a net income margin of 27.58%. Recent Q1 2026 earnings beat expectations, and the company maintains a solid dividend. Analyst consensus is a Buy with a $189.67 price target, though technical indicators suggest near-term consolidation around key support and resistance levels.
The outlook for ATO is positive due to steady earnings growth, customer expansion, and supportive regulatory changes. Risks include high capital expenditures and exposure to energy market volatility. Institutional sentiment is bullish, with no sell ratings, positioning the stock for potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
